Leukemia Research
Volume 25, Issue 9 , Pages 783-791 , 1 September 2001

Poor prognosis acute myelogenous leukemia: 3—biological and molecular biological changes during remission induction therapy

Received 10 April 2000 ,Accepted 21 January 2001.

References 

  1. Preisler HD, Raza A, Larson R, Goldberg J, Tricot G, Carey M, et al. Some reasons for the lack of progress in the treatment of acute myelogenous leukemia. Leuk. Res. 1992;15(9):773–780
  2. Preisler HD, Raza A, Bonomi P, Taylor S, LaFollette S, Leslie W, et al. Regrowth resistance as a likely significant contributor to treatment failure in drug sensitive neoplastic diseases. Cancer Invest. 1997;15(4):358–368
  3. Preisler HD, Raza A. The relationship between tumor proliferation and the response of malignant disease to cytotoxic therapy: Some lessons learned from cell cycle studies. Cancer Res. Ther. Control. 1998;53:170–171
  4. Preisler HD, Venugopal P, Gregory SA, Hsu W-T, Loew J, Adler S, et al. Poor prognosis acute myelogenous leukemia: 1-Response to treatment with high dose cyarabine/mitoxantrone/ethyol (Amifostine). Leuk. Res. 2000;24(8):671–680
  5. Li B, Yang J, Tao M, Nayini J, Horvath E, Chopra H, et al. Poor prognosis acute myelogenous leukemia: 2-Biological and molecular biological characteristics and treatment outcome. Leuk. Res. 2000;24(9):777–789
  6. Preisler HD. Treatment failure in AML. Blood Cells. 1982;8:585–602
  7. Anderlini P, Luna M, Kantarjian HM, O'Brien S, Pierce S, Keating MJ, et al. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 1996;10:600–608
  8. Fourth International Workshop in Leukemia A prospective study of acute nonlymphocytic leukemia, Cancer Genet Cytogenet 1984;11:249.
  9. Li B, Yang J, Andrews C, Chen Y-X, Toofanfard P, Huang RW, Horvath E, Chopra H, Raza A, Preisler HD. Telomerase activity in pre-leukemia and acute myelogenous leukemia, Leuk Lymp 2000;00:1–9.
  10. Raza A, Maheshwari Y, Preisler HD. Differences in cell cycle characteristics amongst patients with acute nonlymphocytic leukemia. Blood. 1987;69(6):1647–1653
  11. Kotelnikov V, Cass L, Coon JS, Spaulding D, Preisler HD. Accuracy of histone H3 messenger RNA in situ hybridization for the assessment of cell proliferation in human tissues, Clin Cancer Res 1997;669–675.
  12. Raza A, Gezer S, Mundle S, Gao X-Z, Alvi S, Borok R, et al. Apoptosis in bone marrow biopsies involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995;86(1):268–276
  13. Gao XZ, Bi S, Chopra H, Devemy E, Venugopal P, Li B, et al. Cytokine gene activity in AML cells in vivo in patients. Leuk. Res. 1998;22:429–438
  14. Tao M, Li B, Nayini J, Andrews CB, Huang R-W, Yang J, Devemy E, Song S, Venugopal P, Preisler HD. SCF, IL1α, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients. Cytokine, in press.
  15. Marchetti A, Buttitta F, Merlo G, Diella F, Pellegrini S, Pepe S. p53 alterations in non- small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res. 1993;15(53(12)):2846–2851
  16. Stratton MR, Fisher C, Gusterson BA, Cooper CS. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res. 1989;15(49(22)):6324–6327
  17. Bos J, Verlanna-de Vries M, van Der EB. Mutations in N-ras predominate in acute myeloid leukemia. Blood. 1987;69(4):1237–1241
  18. Todd AV, Ireland CM, Radloff TJ, Kronenberg H, Il HJ. Analysis of N-ras gene mutations in acute myeloid leukemia by allele specific restriction analysis. Am. J. Hematol. 1991;38(3):207–213
  19. Ferrari S, Grande A, Manfredini R, Tagliafico E, Zucchini P, Torelli G, et al. Expression of interleukins 1, 3, 6, stem cell factor and their receptors in acute leukemia blast cells and in normal peripheral lymphocytes and monocytes. Eur. J. Haematol. 1993;50:141–148
  20. Preisler HD, Raza A, Kukla C, Larson R, Goldberg J, Brownman G. IL1α expression and treatment outcome in acute myelogenous leukemia (AML). Blood. 1991;78(3):849–850
  21. Williams GT, Smith CA, Spooncer E. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature. 1990;343(6255):76–79
  22. Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor ***1 and cancer chemotherapy compounded in myeloid leukemic cells. Blood. 1992;80(7):1750–1757

PII: S0145-2126(01)00032-7

Leukemia Research
Volume 25, Issue 9 , Pages 783-791 , 1 September 2001

Article Tools

* Image Usage & Resolution